- Home
- SWIM vs PHAR Comparison
SWIM vs PHAR Comparison
Compare SWIM & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- PHAR
- Stock Information
- Founded
- SWIM 1956
- PHAR 1988
- Country
- SWIM United States
- PHAR Netherlands
- Employees
- SWIM N/A
- PHAR N/A
- Industry
- SWIM Plastic Products
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- SWIM Industrials
- PHAR Health Care
- Exchange
- SWIM Nasdaq
- PHAR Nasdaq
- Market Cap
- SWIM 839.1M
- PHAR 951.7M
- IPO Year
- SWIM 2021
- PHAR N/A
- Fundamental
- Price
- SWIM $7.27
- PHAR $17.25
- Analyst Decision
- SWIM Hold
- PHAR Strong Buy
- Analyst Count
- SWIM 3
- PHAR 3
- Target Price
- SWIM $7.10
- PHAR $30.00
- AVG Volume (30 Days)
- SWIM 751.3K
- PHAR 19.5K
- Earning Date
- SWIM 11-04-2025
- PHAR 11-06-2025
- Dividend Yield
- SWIM N/A
- PHAR N/A
- EPS Growth
- SWIM N/A
- PHAR N/A
- EPS
- SWIM N/A
- PHAR 0.00
- Revenue
- SWIM $533,235,000.00
- PHAR $362,274,000.00
- Revenue This Year
- SWIM $9.17
- PHAR $17.70
- Revenue Next Year
- SWIM $5.38
- PHAR $12.25
- P/E Ratio
- SWIM N/A
- PHAR $3,140.43
- Revenue Growth
- SWIM 4.12
- PHAR 26.78
- 52 Week Low
- SWIM $4.56
- PHAR $7.35
- 52 Week High
- SWIM $8.46
- PHAR $17.86
- Technical
- Relative Strength Index (RSI)
- SWIM 57.40
- PHAR 63.86
- Support Level
- SWIM $6.13
- PHAR $15.81
- Resistance Level
- SWIM $6.96
- PHAR $17.50
- Average True Range (ATR)
- SWIM 0.32
- PHAR 0.78
- MACD
- SWIM 0.09
- PHAR 0.12
- Stochastic Oscillator
- SWIM 98.27
- PHAR 96.62
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.